Mineralys Therapeutics
- Country
- 🇺🇸United States
- Ownership
- Public
- Established
- 2020-01-01
- Employees
- 28
- Market Cap
- $606.6M
- Website
- http://www.mineralystx.com
- Introduction
Mineralys Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which focuses on developing medicines to target diseases driven by abnormally elevated aldosterone. Its clinical-stage product candidate, lorundrostat, is a proprietary, orally administered, highly selective aldosterone synthase inhibitor that are initially developing for the treatment of cardiorenal conditions affected by abnormally elevated aldosterone, including hypertension and chronic kidney disease. The company was founded by Brian Taylor Slingsby on May 31, 2019 and is headquartered in Radnor, PA.
A Study to Assess the Efficacy and Safety of Lorundrostat in Participants With Obstructive Sleep Apnea and Hypertension
- Conditions
- Obstructive Sleep ApneaHypertension
- Interventions
- Drug: Placebo
- First Posted Date
- 2025-01-21
- Last Posted Date
- 2025-05-15
- Lead Sponsor
- Mineralys Therapeutics Inc.
- Target Recruit Count
- 40
- Registration Number
- NCT06785454
- Locations
- 🇺🇸
The University of Alabama, Tuscaloosa, Alabama, United States
🇺🇸Chandler Clinical Trials, Chandler, Arizona, United States
🇺🇸Preferred Research Partners Inc., Little Rock, Arkansas, United States
Efficacy and Safety of Lorundrostat in Subjects With Uncontrolled and Resistant Hypertension
- Conditions
- Hypertension
- Interventions
- Drug: lorundrostat Dose 1Drug: PlaceboDrug: lorundrostat Dose 2
- First Posted Date
- 2023-12-01
- Last Posted Date
- 2025-02-24
- Lead Sponsor
- Mineralys Therapeutics Inc.
- Target Recruit Count
- 1083
- Registration Number
- NCT06153693
- Locations
- 🇺🇸
Advanced Cardiovascular, LLC - Alexander City Office, Alexander City, Alabama, United States
🇺🇸Central Research Associates, Inc, Birmingham, Alabama, United States
🇺🇸Cardiology, P.C., Birmingham, Alabama, United States
Efficacy and Safety of Lorundrostat in Addition to Sodium-Glucose Cotransporter-2 Inhibitors (SGLT2i) in Subjects With Hypertension and Chronic Kidney Disease (CKD) With Albuminuria
- Conditions
- Chronic Kidney Disease
- Interventions
- Drug: Placebo QD + SGLT2i QD, Washout, Lorundrostat 25mg+SGLT2i QDDrug: Lorundrostat 25mg+SGLT2i QD, Washout, Placebo+SGLT2i QD
- First Posted Date
- 2023-11-29
- Last Posted Date
- 2025-02-21
- Lead Sponsor
- Mineralys Therapeutics Inc.
- Target Recruit Count
- 60
- Registration Number
- NCT06150924
- Locations
- 🇺🇸
Arizona Kidney Disease & Hypertension Centers (AKDHC) - Thunderbird Office, Glendale, Arizona, United States
🇺🇸Arizona Kidney Disease & Hypertension Centers (AKDHC) - Thomas Office, Phoenix, Arizona, United States
🇺🇸Balboa Nephrology Medical Group, Inc. (BNMG) - California Institute of Renal Research (CIRR) - Chula Vista, Chula Vista, California, United States
Open-Label Extension (OLE) Study to Assess Safety, Efficacy, and Tolerability of Lorundrostat in Subjects With Hypertension
- First Posted Date
- 2023-08-01
- Last Posted Date
- 2025-06-15
- Lead Sponsor
- Mineralys Therapeutics Inc.
- Target Recruit Count
- 1400
- Registration Number
- NCT05968430
- Locations
- 🇺🇸
Accel Research Sites (ARS) - Birmingham Clinical Research Unit, Birmingham, Alabama, United States
🇺🇸G & L Research LLC, Foley, Alabama, United States
🇺🇸Chandler Clinical Trials, Chandler, Arizona, United States
A Pivotal Study to Evaluate the Efficacy of Lorundrostat in Subjects with Uncontrolled Hypertension on a Standardized Antihypertensive Medication Regimen
- Conditions
- Hypertension
- Interventions
- Drug: lorundrostat Dose 2Drug: lorundrostat Dose 1Drug: Placebo
- First Posted Date
- 2023-03-15
- Last Posted Date
- 2025-02-18
- Lead Sponsor
- Mineralys Therapeutics Inc.
- Target Recruit Count
- 285
- Registration Number
- NCT05769608
- Locations
- 🇺🇸
Cardiology, P.C. - Birmingham, Birmingham, Alabama, United States
🇺🇸University of Alabama at Birmingham (UAB) - Vascular Biology and Hypertension Program, Birmingham, Alabama, United States
🇺🇸Chandler Clinical Trials, Chandler, Arizona, United States
Trial on the Safety and Efficacy of MLS-101 in Patients With Uncontrolled Hypertension
- Conditions
- Hypertension, Renal
- Interventions
- Other: Placebo (Part I)Drug: MLS-101 (Part I)Other: Placebo (Part II)Drug: MLS-101 (Part II)
- First Posted Date
- 2021-08-12
- Last Posted Date
- 2024-01-05
- Lead Sponsor
- Mineralys Therapeutics Inc.
- Target Recruit Count
- 200
- Registration Number
- NCT05001945
- Locations
- 🇺🇸
Site 103, Lincoln, California, United States
🇺🇸Site 129, Torrance, California, United States
🇺🇸Site 135, Tustin, California, United States